MiBio Meeting Series
The MIBio conference series engages leading experts from industry and academia in a discussion on how the latest molecular interaction-based discoveries can be exploited in biopharmaceutical formulation to produce more effective, patient-friendly, and safer therapeutic products.
The 12th MIBio2024 Conference (https://lnkd.in/emQiq3CE) took place in the beautiful, theatrical surroundings of Downing College at the University of Cambridge, UK. This dynamic, full-day event featured a series of insightful presentations, an engaging panel discussion, and an array of posters, offering outstanding networking opportunities for over 70 participants from both academia and industry. In support of early career scientists, we awarded 10 bursaries to facilitate their poster presentations.
This year's conference emphasized advancements in subcutaneous delivery. Professor Samir Mitragotri from Harvard University presented the interesting development of the Subcutaneous Co-Culture Tissue-on-a-chip for Injection Simulation (SubCuTIS) and the innovative use of ionic liquids to enhance subcutaneous injection capabilities for therapeutic proteins. Dr. Kishore Ravuri from Roche shared essential insights into formulating high-concentration protein solutions. Dr. Isabelle Trayton and Dr. Belal Hanafy from AstraZeneca discussed predicting monoclonal antibody (mAb) subcutaneous bioavailability using the SCISSOR platform combined with data modeling. Dr. Thomas Birngruber from Joanneum Research introduced open flow microperfusion technology, a novel approach to studying tissue-specific pharmacokinetics (PK) and pharmacodynamics (PD), thus enhancing our understanding of local drug bioavailability and distribution. Lastly, Dr. Sumantha Dayananda from ten123 Health provided valuable guidance on optimizing developability strategies for early-stage subcutaneous formulation development.
We extend our gratitude to all the panellists, including Professor Samir Mitragotri, Dr. Ana Gomes dos Santos, Dr. Kishore Ravuri, Dr. Bernardo Perez-Ramirez, and Dr. Iain Simpson, for sharing their expertise on various subcutaneous delivery topics. These included discussions on devices, high-concentration and larger-volume delivery, patient experience, bioavailability, commercial considerations, and the integration of therapeutics.
The conference was co-organized by Dr. Jan Jezek, Dr. Nicholas Darton, Dr. Bernardo Perez-Ramirez, Dr. Tejash Shah, Prof. Steve Harding, Dr. Bin Yang and Dr. Priyanka Dey. The committee members represented the Formulation Science and Technology Group (FST), the Joint Colloids Group of the Society of Chemical Industry (SCI), the Royal Society of Chemistry (RSC), and the Academy of Pharmaceutical Sciences (APS).
MiBio 2023 (11th)
The 11th MIbio2023 conference was held at the exquisite Howard Theatre, Downing College of University of Cambridge in Cambridge, UK. This one-day event was marked by a series of enlightening presentations, exciting posters and provided invaluable networking opportunities with representatives from both academia and industry. This conference was co-organized by the Royal Society of Chemistry (RSC) RSC Formulation Science and Technology (FSTG), and the Joint Colloids Group of the Society of Chemical Industry Chemical Industry (SCI) and Royal Society of Chemistry, together with the Academy of Pharmaceutical Science (APS).
This year's conference centred around cutting-edge advancements in biopharmaceutical product development. Dr. Didier PERTUY(Sanofi) discussed how drug delivery technologies are shaped by diverse modalities, emphasizing customer needs and ecosystems. Dr. Katie C. (AstraZeneca) explored the application of human factors in patient-centric dosage and device development, emphasizing a user-centred approach. Dr. Maria Chiara Arno (University of Birmingham) introduced a novel method for precision polymer particle manufacturing, potentially revolutionizing drug delivery applications. Dr. Stephen Buckley (Novo Nordisk), presented advanced strategies for oral peptide/protein delivery, delving into chemistry, enhancers, and novel devices/technologies. Additionally, Dr. Alistair Taverner (University of Bath) shared insights on the Permeable Inhibitor of Phosphatase (PIP) peptide, enhancing oral peptide absorption by targeting endogenous biological permeability regulation. Lastly, Professor Paul Dalby (University College London) elucidated the degradation and stabilization mechanisms in biologic formulations, employing biophysical analysis and molecular dynamics (MD) simulations.
Beyond the exceptional presentations, panel discussions explored strategies for biopharmaceutical drug delivery, including enhanced devices, patient-centric designs, and human factors. Formulation challenges for parenteral (subcutaneous, intravenous) administration were addressed, alongside innovative approaches involving alternative administration routes.
MiBio 2023 ♦ MiBio 2022 ♦ MiBio 2019 ♦ MiBio 2018
MiBio 2016 ♦ MiBio 2015 ♦ MiBio 2014 ♦ MiBio 2013 ♦ MiBio 2012